Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Insys Therapeutics has launched Subsys (fentanyl sublingual spray), used for the management of persistent cancer pain.
Subscribe to our email newsletter
Subsys is a sublingual spray formulation of free fentanyl in a single unit-dose delivery device which disperses a fine mist over a broad sublingual area.
The fentanyl sublingual spray is available in 100mcg through 1600mcg doses, and indicated for cancer patients aged 18 years and old who are tolerant to opioid therapy for their underlying persistent cancer pain.
In clinical trials, Subsys reached the primary endpoint of summed pain intensity differences at 30 minutes post treatment (SPID30), and also achieved a mean absolute bioavailability of fentanyl of 76%.
Carolinas Pain Institute and Wake Forest University Dr. Richard Rauck said the easy-to-use sublingual spray produces effective, potent and rapid pain relief in cancer patients.